Entering text into the input field will update the search result below

Cellectis, Primera Therapeutics to develop therapies for mitochondrial diseases

Dec. 29, 2022 5:17 PM ETCellectis S.A. (CLLS)By: Anuron Mitra, SA News Editor

Mitochondrion structure

Artur Plawgo

  • Primera Therapeutics and French biotech Cellectis (NASDAQ:CLLS) on Thursday said they would collaborate to develop therapies for mitochondrial diseases.
  • Primera and CLLS will work collaboratively to edit mutations of the mitochondrial DNA to treat the root cause

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About CLLS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Cellectis S.A.
Innate Pharma S.A.
Harpoon Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Mesoblast Limited
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.